Diversity in the Clinical Course and Outcome of COVID-19 in Patients with Different Inborn Errors of Immunity can be Associated with the Type of Error.

IF 0.7 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Advanced biomedical research Pub Date : 2024-11-30 eCollection Date: 2024-01-01 DOI:10.4103/abr.abr_134_23
Negin Salemi, Behrokh Shojaie, Paria Bolourinejad, Roya Sherkat, Aryana Zamanifar, Farhoodeh Ghaedrahmati, Mahdieh Azizi, Hamid Aria
{"title":"Diversity in the Clinical Course and Outcome of COVID-19 in Patients with Different Inborn Errors of Immunity can be Associated with the Type of Error.","authors":"Negin Salemi, Behrokh Shojaie, Paria Bolourinejad, Roya Sherkat, Aryana Zamanifar, Farhoodeh Ghaedrahmati, Mahdieh Azizi, Hamid Aria","doi":"10.4103/abr.abr_134_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The relationship between inborn errors of immunity (IEIs) and COVID-19 severity and incidence rates remains unclear due to limited and diverse data. This study aimed to address this gap by identifying specific IEIs associated with an increased risk of severe COVID-19 or a predisposition to severe disease before vaccination.</p><p><strong>Materials and methods: </strong>Data were collected from the medical records of 15 patients with various IEIs, supplemented by interviews with individuals from an IEIs registry who had experienced COVID-19 before vaccination.</p><p><strong>Results: </strong>Among the participants, only three patients (20%) experienced severe-prolonged COVID-19. Notably, this severity was predominantly observed in two male patients with Bruton's disease (BD) and one female patient with autosomal recessive hypogammaglobinemia. Moderate and severe COVID-19 cases were equally distributed (13.33%). In the female subgroup, one patient with common variable immunodeficiency and another with combined immunodeficiency experienced moderate and severe COVID-19, respectively. Conversely, both male patients with moderate and severe COVID-19 had BD.</p><p><strong>Conclusion: </strong>Despite the limited number of severe cases, the absence of cytokine storm manifestation suggests potential protective mechanisms, possibly due to intravenous immunoglobulin therapy and inherent deficiencies within cytokine-producing cells (B and T cells). While IEIs may not be significant risk factors for COVID-19, they offer promising avenues for further research into therapeutic strategies targeting specific immune system components to mitigate severe COVID-19.</p>","PeriodicalId":94292,"journal":{"name":"Advanced biomedical research","volume":"13 ","pages":"112"},"PeriodicalIF":0.7000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665184/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/abr.abr_134_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The relationship between inborn errors of immunity (IEIs) and COVID-19 severity and incidence rates remains unclear due to limited and diverse data. This study aimed to address this gap by identifying specific IEIs associated with an increased risk of severe COVID-19 or a predisposition to severe disease before vaccination.

Materials and methods: Data were collected from the medical records of 15 patients with various IEIs, supplemented by interviews with individuals from an IEIs registry who had experienced COVID-19 before vaccination.

Results: Among the participants, only three patients (20%) experienced severe-prolonged COVID-19. Notably, this severity was predominantly observed in two male patients with Bruton's disease (BD) and one female patient with autosomal recessive hypogammaglobinemia. Moderate and severe COVID-19 cases were equally distributed (13.33%). In the female subgroup, one patient with common variable immunodeficiency and another with combined immunodeficiency experienced moderate and severe COVID-19, respectively. Conversely, both male patients with moderate and severe COVID-19 had BD.

Conclusion: Despite the limited number of severe cases, the absence of cytokine storm manifestation suggests potential protective mechanisms, possibly due to intravenous immunoglobulin therapy and inherent deficiencies within cytokine-producing cells (B and T cells). While IEIs may not be significant risk factors for COVID-19, they offer promising avenues for further research into therapeutic strategies targeting specific immune system components to mitigate severe COVID-19.

不同先天性免疫错误患者COVID-19临床病程和结局的差异可能与免疫错误类型有关。
背景:由于数据有限和多样化,先天性免疫错误(IEIs)与COVID-19严重程度和发病率之间的关系尚不清楚。本研究旨在通过确定在接种疫苗前与严重COVID-19风险增加或严重疾病易感性相关的特定肠道免疫缺陷来解决这一差距。材料和方法:数据收集自15名不同肠道感染患者的医疗记录,并辅以对肠道感染登记处在接种疫苗前经历过COVID-19的个人的访谈。结果:在参与者中,只有3名患者(20%)经历了严重的长期COVID-19。值得注意的是,这种严重程度主要见于两名患有布鲁顿病(BD)的男性患者和一名患有常染色体隐性低γ -血红蛋白血症的女性患者。中、重度病例平均分布(13.33%)。在女性亚组中,一名患有常见可变免疫缺陷的患者和另一名患有联合免疫缺陷的患者分别经历了中度和重度COVID-19。结论:尽管重症病例数量有限,但细胞因子风暴表现的缺失提示潜在的保护机制,可能是由于静脉注射免疫球蛋白治疗和细胞因子产生细胞(B细胞和T细胞)固有的缺陷。虽然iei可能不是COVID-19的重要风险因素,但它们为进一步研究针对特定免疫系统成分的治疗策略提供了有希望的途径,以减轻严重的COVID-19。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信